Last reviewed · How we verify
NCT00004689
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
Phase 2 trial testing amithiozone in Mycobacterium Avium-intracellulare Infection in 50 participants. Completed in 1 September 1998.
Quick facts
| Lead sponsor | National Jewish Health |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 1991 |
| Estimated completion | 1 September 1998 |
Drugs / interventions tested
- amithiozone — full drug profile →
- clarithromycin (clarithromycin) — full drug profile →
- ethambutol (ETHAMBUTOL) — full drug profile →
- rifampin — full drug profile →
- streptomycin
Conditions studied
- Mycobacterium Avium-intracellulare Infection — all drugs for Mycobacterium Avium-intracellulare Infection →
Sponsor
National Jewish Health — full company profile →
Who can join
18 and older, any sex, with Mycobacterium Avium-intracellulare Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium avium complex (MAC) pulmonary disease. II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC infection. III. Determine the safety and tolerance of amithiozone with chronic dosing in these patients. IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol, kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
<i>M. avium Complex</i> Pulmonary Infections: Therapeutic Obstacles and Progress in Drug Development.
Charrier ESA, Dassonville-Klimpt A, Andréjak C, Sonnet P. · · 2025 · cited 2× · PMID 40573286 · DOI 10.3390/ph18060891
Verify or expand the search:
- PubMed search for NCT00004689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Jewish Health trials
Trials by the same sponsor.
- NCT06435520 — Enhancing Hypnotic Medication Discontinuation in Primary Care · Phase 4 · recruiting
- NCT06262282 — Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria · enrolling by invitation
- NCT06155747 — Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt) · recruiting
- NCT04724278 — Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study · unknown
- NCT05313087 — COVID-19 Vaccine Response in Chronic Respiratory Conditions · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00004689 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Jewish Health
- Last refreshed: 24 March 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing